Clinical Trial

A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2026 (before its estimated May 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
Neutralizing antibody seroconversion rate and geometric mean concentration in seronegative participants of each group at 14 days after the first dose of immunization. The seroconversion rate of neutralizing antibodies 42 days after the first dose among seronegative participants before vaccination in each group
Trial Details
NCT Number NCT07500207
Lead Sponsor Changchun BCHT Biotechnology Co.
Conditions Rabies Prevention
Enrollment 3,000 participants
Start Date 2026-03-04
Primary Completion 2026-05-25 (estimated)
Study Completion 2027-03-25 (estimated)
Updated on ClinicalTrials.gov 2026-03-30